Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptomatic Respiratory Disease Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00810693
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 9, 2026, 3:03 AM EDT
Recruiting Phase 2 Interventional

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

NCT06262321
View directory record Official record
Conditions
Stage 4 NSCLC, Radiotherapy
Interventions
Prophylactic Palliative Radiotherapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

NCT04724720
View directory record Official record
Conditions
Covid-19
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 9, 2026, 3:03 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 9, 2026, 3:03 AM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
La Mesa, California • Rancho Mirage, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

NCT00402987
View directory record Official record
Conditions
Pharyngitis
Interventions
celecoxib, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 18 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

NCT00863681
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 9, 2026, 3:03 AM EDT
Completed No phase listed Observational

Vital Sensor Monitors for CV19 Detection

NCT04635787
View directory record Official record
Conditions
Covid19
Interventions
ANNE One
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 2 Interventional

Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

NCT00552461
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, Primary Disease
Interventions
rituximab
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
Ifetroban Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Lancaster, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

NCT04540406
View directory record Official record
Conditions
Suspected or Confirmed COVID-19
Interventions
NBT-NM108, Usual Care Only
Drug · Other
Lead sponsor
Notitia Biotechnologies Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 3 Interventional

A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat

NCT00647829
View directory record Official record
Conditions
Pharyngitis
Interventions
valdecoxib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Storrs, Connecticut • Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

NCT05799495
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
PF-07817883, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
53
States / cities
Cullman, Alabama • Phoenix, Arizona • Surprise, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 9, 2026, 3:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

NCT04508023
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Rivaroxaban, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 9, 2026, 3:03 AM EDT
Terminated Not applicable Interventional Results available

Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

NCT04040244
View directory record Official record
Conditions
Pneumonitis, Nonsmall Cell Lung Cancer Stage III
Interventions
Exhaled Breath Collection, Blood sample
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 9, 2026, 3:03 AM EDT
Terminated Phase 2 Interventional Results available

DISulfiram for COvid-19 (DISCO) Trial

NCT04485130
View directory record Official record
Conditions
Covid19
Interventions
Disulfiram, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fresno, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 9, 2026, 3:03 AM EDT
Recruiting Phase 2 Interventional

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT06817889
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
Interventions
Remdesivir, Survey Administration, Biospecimen Collection, Nasal Swab
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Duarte, California • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 3:03 AM EDT
Active, not recruiting Not applicable Interventional

The ACES Study for Aseptic Pleural Effusion

NCT06210685
View directory record Official record
Conditions
Pleural Effusion
Interventions
Automatic Continuous Effusion Shunt implantation
Device
Lead sponsor
Pleural Dynamics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Hollywood, Florida • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT02367313
View directory record Official record
Conditions
Asthma
Interventions
Vapendavir, Placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 9, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00660179
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
macitentan (ACT-064992), placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 9, 2026, 3:03 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

NCT02138825
View directory record Official record
Conditions
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 9, 2026, 3:03 AM EDT
Recruiting Not applicable Interventional

Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis

NCT07191860
View directory record Official record
Conditions
Adult Subjects With Symptomatic Benign Airway Obstruction, Adult Benign Central Airway Stenosis, Adult Tracheobronchial Stenosis, Tracheal Stenosis, Central Airway Stenosis, Central Airway Obstruction
Interventions
The Airiver Pulmonary drug-coated balloon (DCB) dilation, Commercial airway balloon dilation
Combination Product · Device
Lead sponsor
Airiver Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 9, 2026, 3:03 AM EDT